Use of fenoTRACK Device for Monitoring Changes of Fractional Exhaled Nitric Oxide (FeNO) in Uncontrolled Asthma Subjects and Controlled Asthma Subjects

Официальное название

A Combined Prospective, Multicenter, Non-Randomized, Open-Label, Point-of-Care and Home Use Pivotal Study of the fenoTRACK Device for Monitoring Changes of Fractional Exhaled Nitric Oxide (FeNO) in Non-Steroid-Treated Adult and Pediatric Uncontrolled Asthma Subjects and a Prospective Multicenter Clinical Precision Evaluation for Point-of-Care and Home Use in Adult and Pediatric Controlled Asthma Subjects

Обзор

This study incorporates objectives directed at two subject cohorts: 1. Uncontrolled Adult and Pediatric Asthma Subjects: To demonstrate a statistically significant and clinically meaningful decline in Point Of Care (POC) FeNO as measured by the fenoTRACK device, after an approximately 2-week course of corticosteroid therapy in adults and children with non-steroid treated uncontrolled asthma. 2. Controlled Adult and Pediatric Asthma Subjects: * To evaluate within-session clinical precision during Visit 1 and Visit 2 for the fenoTRACK device for simulated at home FeNO, and at POC * To evaluate within-session clinical precision for home fenoTRACK use

Подробное описание

1. Uncontrolled Adult and Pediatric Asthma Subjects The primary objective is: To demonstrate a statistically significant and clinically meaningful decline in POC FeNO as measured by the fenoTRACK device from Visit 1 (V1) to Visit 2 (V2), after an approximately 2-week course of corticosteroid therapy in adults and children with non-steroid treated uncontrolled asthma.

Secondary objectives: * To demonstrate that the decline in FeNO on the fenoTRACK device is accompanied by improvements in asthma outcome measures including the 7-item asthma control questionnaire (ACQ) score or asthma control questionnaire - Interviewer Administered (ACQ-IA), lung function as assessed by spirometry, and rescue medication use * To demonstrate clinical accuracy of FeNO measurements on the fenoTRACK device by comparison of within-session FeNO values acquired in a simulated at home FeNO versus FeNO values acquired at the POC at V1 and V2 * To record how many efforts are required to achieve 2 valid FeNO results on the fenoTRACK device for simulated at home FeNO and POC FeNO measurements at V1 and V2, and between V1 and V2 2. Controlled Adult and Pediatric Asthma Subjects

Co-primary objectives:

* To evaluate within-session clinical precision during V1 and V2 for the fenoTRACK device for simulated at home FeNO, and at POC To evaluate within-session clinical precision for home fenoTRACK use Secondary objectives:To demonstrate clinical accuracy of FeNO measurements on the fenoTRACK device by comparison of within-session FeNO values acquired for simulated at home FeNO versus FeNO values acquired at the POC at V1 and V2 * To record how many efforts are required to achieve 2 valid FeNO results on the fenoTRACK device for simulated at home FeNO and POC measurements at V1 and V2, and between V1 and V2

Вмешательства

• Устройство fenoTRACK Device
  Home FeNO Monitoring: FeNO measurement will be performed. POC Longitudinal Response to Treatment: FeNO measurement will be performed in the office both the simulated home environment and POC environment.

Первичные конечные точки

• Uncontrolled Cohort - Magnitude of change in FeNO Values [Срок оценки: Visit 2 (Day 14)]

Вторичные конечные точки (6)

• Uncontrolled Cohort - Magnitude of change (POC) [Срок оценки: Visit 2 (Day 14)]
• Uncontrolled Cohort - Magnitude of change (Home Use) [Срок оценки: Day 1 and Day 2 AM and PM FeNO values compared to average of the last 2 Days prior to Visit 2]
• Uncontrolled Cohort - Change in 7-item ACQ/ACQ-IA [Срок оценки: Visit 2 (Day 14)]
• Uncontrolled Cohort - Change in best spirometry measures [Срок оценки: Visit 2 (Day 14)]
• Controlled cohort - Clinical precision based on the first 2 FeNO results - Within-session clinical precision in a simulated home-use environment (V1 and V2) - Within-session clinical precision at the POC (V1 and V2) - Clinical precision at home [Срок оценки: Visit 2 (Day 14)]
• Controlled cohort - Accuracy of FeNO results by comparison of paired within-individual FeNO values acquired in a simulated home-use environment versus FeNO values acquired at the POC at both V1 and V2 [Срок оценки: Visit 2 (Day 14)]

Критерии участия

Inclusion Criteria Uncontrolled Cohort:

• The subject is male or female age 5 years and above
• The subject and/or their Legally Authorized Representative (LAR) in the case of a minor has signed an Informed Consent Form (ICF) and Assent (as applicable per IRB requirements) and understands the risks and benefits of the study
• The subject has a diagnosis of asthma
• The subject is willing and able to perform all study procedures
• The subject must have uncontrolled asthma as defined by the presence on at least 2 days per week (can be non-consecutive days) in the 7 days prior to V1 of at least 3 symptoms from the following list:

i. Cough ii. Wheezing iii. Shortness of breath iv. Chest tightness v. Nocturnal awakening with asthma vi. Limitation in activity due to asthma

• The subject has a FeNO value based on the first measurement of at least 30 ppb if an adult or at least 25 ppb if <18 years old measured on a cleared FeNO device (e.g., NIOX VERO®)

Inclusion Criteria Controlled Cohort:

• The subject is male or female age 5 years and above
• The subject and/or their Legally Authorized Representative (LAR) in the case of a minor has signed an Informed Consent Form (ICF) and Assent (as applicable per IRB requirements) and understands the risks and benefits of the study
• The subject has an established diagnosis of asthma for at least 180 days prior to V1
• The subject is willing and able to perform all study procedures

Exclusion Criteria Uncontrolled:

• The subject is in need of immediate referral to the emergency department
• The subject has taken the following medications in the indicated period before V1:

• OCS within 4 weeks
• ICS within 2 weeks
• Biologic therapies (e.g., omalizumab or dupilumab) within 12 weeks. Note: Use of as needed ICS+SABA is also exclusionary in the 2 weeks prior to V1
• The subject has a contraindication to corticosteroids.
• The subject has demonstrated significant non-compliance during a previous clinical trial
• The subject participated in any clinical study involving a drug, biologic, or device within 30 days prior to V1 or within 5 half-lives for drugs, whichever duration is shorter
• The subject has other significant respiratory conditions, e.g., Chronic Obstructive Pulmonary Disease, cystic fibrosis
• Subject is an employee/relative of the following:

• Biometry Inc.
• Contract Research Organization(s) running the study
• Investigational Site
• Study Vendors
• Any other condition(s), that in the Investigator's opinion, make it undesirable for the subject to participate in the study
• A ≥ 10 pack-year history of smoking or smoking in the 180 days prior to V1 (pack years = average packs/day x years of exposure) Note: smoking includes cigarettes, electronic cigarettes, cigars, and chewing or dipping tobacco
• Pregnant or nursing subjects

Exclusion Criteria Controlled:

• The subject has other significant respiratory conditions, e.g., Chronic Obstructive Pulmonary Disease, cystic fibrosis
• The subject has demonstrated significant non-compliance during a previous clinical trial
• The subject participated in any clinical study involving a drug, biologic, or device within 30 days prior to V1 or within 5 half-lives for drugs, whichever duration is shorter.
• Subject is an employee/relative of the following:

• Biometry Inc.
• Contract Research Organization(s) running the study
• Investigational Site
• Study Vendors
• Any other condition(s), that in the Investigator's opinion, make it undesirable for the subject to participate in the study
• A ≥ 10 pack-year history of smoking or smoking in the 180 days prior to V1 (pack years = average packs/day x years of exposure) Note: smoking includes cigarettes, electronic cigarettes, cigars, and chewing or dipping tobacco
• Pregnant or nursing subjects

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения

Когортное

Центры проведения

США · 13 центров

• Bensch Clinical Research LLC — Stockton
• AllerVie Clinical Research — Panama City
• AllerVie Clinical Research — Columbus
• Paul A Shapero MD — Bangor
• AllerVie Clinical Research — Ellicott City
• AllerVie Clinical Research — Glenn Dale
• Nebraska Medical Research Institute, Inc. — Bellevue
• Allergy Partners Clinical Research — Asheville
• … и ещё 5 центров

Идентификаторы

NCT: NCT07228026 · F1

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗